nach oben

Neuropsychology Review

Erschienen in:

01.12.2009 | Review

Beta-Amyloid Deposition and the Aging Brain

verfasst von: Karen M. Rodrigue, Kristen M. Kennedy, Denise C. Park

Erschienen in: Neuropsychology Review | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

A central issue in cognitive neuroscience of aging research is pinpointing precise neural mechanisms that determine cognitive outcome in late adulthood as well as identifying early markers of less successful cognitive aging. One promising biomarker is beta amyloid (Aβ) deposition. Several new radiotracers have been developed that bind to fibrillar Aβ providing sensitive estimates of amyloid deposition in various brain regions. Aβ imaging has been primarily used to study patients with Alzheimer’s Disease (AD) and individuals with Mild Cognitive Impairment (MCI); however, there is now building data on Aβ deposition in healthy controls that suggest at least 20% and perhaps as much as a third of healthy older adults show significant deposition. Considerable evidence suggests amyloid deposition precedes declines in cognition and may be the initiator in a cascade of events that indirectly leads to age-related cognitive decline. We review studies of Aβ deposition imaging in AD, MCI, and normal adults, its cognitive consequences, and the role of genetic risk and cognitive reserve.

This bimodal distribution may serve to highlight the arbitrary nature of a categorical MCI group and emphasizes the continuum of cognitive performance from normal to AD, with MCI being a mid-point of this continuum.

Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., et al. (2008). Frequent amyloid deposition without significant cognitive impairment among the elderly. Archives of Neurology, 65, 1509–1517.CrossRefPubMed

Andreasen, N., Minthon, L., Vanmechelen, E., Vanderstichele, H., Davidsson, P., Winblad, B., et al. (1999). Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer’s disease in patients with mild cognitive impairment. Neuroscience Letters, 273, 5–8.CrossRefPubMed

Andrews-Hanna, J. R., Snyder, A. Z., Vincent, J. L., Lustig, C., Head, D., Raichle, M. E., et al. (2007). Disruption of large-scale brain systems in advanced aging. Neuron, 56, 924–935.CrossRefPubMed

Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., et al. (2006). Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology, 66, 1837–1844.CrossRefPubMed

Bourgeat, P., Villemagne, V.L., Fripp, J., Pike, K.E., Raniga, P., Acosta, O., et al. (2009). Relation between amyloid burden, brain atrophy and memory in Alzheimer’s disease. Alzheimer’s Association 2009 International Conference on Alzheimer’s Disease (ICAD 2009), July.

Braak, H., & Braak, E. (1996). Evolution of the neuropathology of Alzheimer’s disease. Acta Neurologica Scandinavica, 165, 3–12.

Braskie, M.N., Klunder, A.D., Hayashi, K.M., Protas, H., Kepe, V., Miller, K. J., et al. (2008). Plaque and tangle imaging and cognition in normal aging and Alzheimer’s disease. Neurobiology of Aging. doi:10.1016/j.neurobiolaging.2008.09.012.

Buckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., et al. (2005). Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory. Journal of Neuroscience, 25, 7709–7717.CrossRefPubMed

Buckner, R. L., Andrews-Hanna, J. R., & Schacter, D. L. (2008). The brain’s default network: anatomy, function, and relevance to disease. Annals of the New York Academy of Sciences, 1124, 1–38.CrossRefPubMed

Buckner, R. L., Sepulcre, J., Talukdar, T., Krienen, F. M., Liu, H., Hedden, T., et al. (2009). Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer’s disease. Journal of Neuroscience, 29, 1860–1873.CrossRefPubMed

Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science, 261, 921–923.CrossRefPubMed

Dickerson, B. C., Bakkour, A., Salat, D. H., Feczko, E., Pacheco, J., Greve, D. N., et al. (2009). The cortical signature of Alzheimer’s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cerebral Cortex, 19, 497–510.CrossRefPubMed

Dickson, D. W., Crystal, H. A., Mattiace, L. A., Masur, D. M., Blau, A. D., Davies, P., et al. (1992). Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiology of Aging, 13, 179–189.CrossRefPubMed

Diniz, B. S., Pinto, J. A., & Forlenza, O. V. (2008). Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer’s disease? A systematic review and meta-analysis of the literature. World Journal of Biological Psychiatry, 9, 172–182.CrossRefPubMed

Drzezga, A., Grimmer, T., Henriksen, G., Mühlau, M., Perneczky, R., Miederer, I., et al. (2009). Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology, 72, 1487–1494.CrossRefPubMed

Edison, P., Archer, H. A., Hinz, R., Hammers, A., Pavese, N., Tai, Y. F., et al. (2007). Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology, 68, 501–508.CrossRefPubMed

Farlow, M. R., He, Y., Tekin, S., Xu, J., Lane, R., & Charles, H. C. (2004). Impact of APOE in mild cognitive impairment. Neurology, 63, 1898–1901.PubMed

Farrer, L. A., Cupples, L. A., Haines, J. L., Hyman, B., Kukull, W. A., Mayeux, R., et al. (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease meta analysis consortium. Journal of the American Medical Association, 278, 1349–1356.CrossRefPubMed

Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A., et al. (2008). PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiology of Aging, 29, 1456–1465.CrossRefPubMed

Fotenos, A. F., Mintun, M. A., Snyder, A. Z., Morris, J. C., & Buckner, R. L. (2008). Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. Archives of Neurology, 65, 113–120.CrossRefPubMed

Fripp, J., Bourgeat, P., Acosta, O., Raniga, P., Modat, M., Pike, K. E., et al. (2008). Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer’s disease, mild cognitive impairment and healthy aging. Neuroimage, 43, 430–439.CrossRefPubMed

Ghisletta, P., & Lindenberger, U. (2003). Age-based structural dynamics between perceptual speed and knowledge in the Berlin aging study: direct evidence for ability dedifferentiation in old age. Psychology and Aging, 18, 696–713.CrossRefPubMed

Greicius, M. D., Krasnow, B., Reiss, A. L., & Menon, V. (2003). Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proceedings of the National Academy of Sciences of the United States of America, 100, 253–258.CrossRefPubMed

Grimmer, T., Riemenschneider, M., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., et al. (2009). Beta amyloid in Alzheimer’s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biological Psychiatry, 65, 927–934.CrossRefPubMed

Grundman, M., Sencakova, D., Jack, C. R., Jr., Petersen, R. C., Kim, H. T., Schultz, A., et al. (2002). Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. Journal of Molecular Neuroscience, 19, 23–27.CrossRefPubMed

Gutchess, A. H., Welsh, R. C., Hedden, T., Bangert, A., Minear, M., Liu, L. L., et al. (2005). Aging and the neural correlates of successful picture encoding: frontal activations compensate for decreased medial-temporal activity. Journal of Cognitive Neuroscience, 17, 84–96.CrossRefPubMed

Hedden, T., & Gabrieli, J. D. E. (2004). Insights into the ageing mind: a view from cognitive neuroscience. Nature Reviews Neuroscience, 5, 87–97.CrossRefPubMed

Ichise, M., Plett, S., Joshi, A., Stern, Y., van Heertum, R., Lowe, V., et al. (2008). Quantitative comparison of three novel ¹⁸F-labeled ligands for PET imaging of brain amyloid-β plaques in Alzheimer’s disease. Journal of Nuclear Medicine, 49, 214.

Ingelsson, M., Fukumoto, H., Newell, K. L., Growdon, J. H., Hedley-Whyte, E. T., Frosch, M. P., et al. (2004). Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology, 62, 925–931.PubMed

Jack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., et al. (2008). 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain, 131, 665–680.CrossRefPubMed

Jack, C. R., Jr., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., et al. (2009). Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain, 132, 1355–1365.CrossRefPubMed

Jagust, W. (2009a). Mapping brain beta-amyloid. Current Opinion in Neurology, 22, 356–361.CrossRefPubMed

Jagust, W. (2009b). Amyloid + activation = Alzheimer’s? Neuron, 63, 141–143.CrossRefPubMed

Jiang, Q., Lee, C. Y., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., et al. (2008). ApoE promotes the proteolytic degradation of Abeta. Neuron, 58, 681–693.CrossRefPubMed

Josephs, K. A., Whitwell, J. L., Ahmed, Z., Shiung, M. M., Weigand, S. D., Knopman, D. S., et al. (2008). Beta-amyloid burden is not associated with rates of brain atrophy. Annals of Neurology, 63, 204–212.CrossRefPubMed

Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., et al. (2003). APP processing and synaptic function. Neuron, 37, 925–937.CrossRefPubMed

Katzman, R., Terry, R., DeTeresa, R., Brown, T., Davies, P., Fuld, P., et al. (1988). Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Annals of Neurology, 23, 138–144.CrossRefPubMed

Kemppainen, N. M., Aalto, S., Wilson, I. A., Någren, K., Helin, S., Brück, A., et al. (2006). Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology, 67, 1575–1580.CrossRefPubMed

Kemppainen, N. M., Aalto, S., Wilson, I. A., Någren, K., Helin, S., Brück, A., et al. (2007). PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology, 68, 1603–1606.CrossRefPubMed

Kemppainen, N. M., Aalto, S., Karrasch, M., Någren, K., Savisto, N., Oikonen, V., et al. (2008). Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer’s disease. Annals of Neurology, 63, 112–118.CrossRefPubMed

Klunk, W. E., & Mathis, C. A. (2008). The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Current Opinion in Neurology, 21, 683–687.CrossRefPubMed

Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., et al. (2004). Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Annals of Neurology, 55, 306–319.CrossRefPubMed

Li, Y., Rinne, J. O., Mosconi, L., Pirraglia, E., Rusinek, H., DeSanti, S., et al. (2008). Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease. European Journal of Nuclear Medicine and Molecular Imaging, 35, 2169–2181.CrossRefPubMed

Linazasoro, G. (2008). Imaging beta-amyloid burden in aging and dementia. Neurology, 70, 1649–1650.CrossRefPubMed

Lopresti, B. J., Klunk, W. E., Mathis, C. A., Hoge, J. A., Ziolko, S. K., Lu, X., et al. (2005). Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. Journal of Nuclear Medicine, 46, 1959–1972.PubMed

Mintun, M. A., Larossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., et al. (2006). [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology, 67, 446–452.CrossRefPubMed

Mormino, E. C., Kluth, J. T., Madison, C. M., Rabinovici, G. D., Baker, S. L., Miller, B. L., et al. (2009). Episodic memory loss is related to hippocampal-mediated {beta}-amyloid deposition in elderly subjects. Brain, 132, 1310–1323.CrossRefPubMed

Morris, J. C., Roe, C. M., & Mintun, M. A. (2009). APOE status predicts PiB-positivity in nondemented aging: evidence for Preclinical Alzheimer’s disease. Neurology, 72, A92.CrossRef

Nelissen, N., Vandenbulcke, M., Fannes, K., Verbruggen, A., Peeters, R., Dupont, P., et al. (2007). Abeta amyloid deposition in the language system and how the brain responds. Brain, 130, 2055–2069.CrossRefPubMed

Nitsch, R. M., Farber, S. A., Growdon, J. H., & Wurtman, R. J. (1993). Release of amyloid beta-protein precursor derivatives by electrical depolarization of rat hippocampal slices. Proceedings of the National Academy of Sciences, 90, 5191–5193.CrossRef

Nordberg, A. (2008). Amyloid imaging in Alzheimer’s disease. Neuropsychologia, 46, 1636–1641.CrossRefPubMed

Nordlund, A., Rolstad, S., Klang, O., Lind, K., Pedersen, M., Blennow, K., et al. (2008). Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI. Journal of the International Neuropsychological Society, 14, 582–590.CrossRefPubMed

Park, D. C., & Goh, J. O. (2009). Successful aging. In J. Cacioppo & G. Berntson (Eds.), Handbook of Cognitive Neuroscience for the Behavioral Sciences, Ch. 61 (pp. 1203–1219). Hoboken: Wiley.

Park, D. C., & Reuter-Lorenz, P. A. (2009). The adaptive brain: aging and neurocognitive scaffolding. Annual Review of Psychology, 60, 173–196.CrossRefPubMed

Park, D. C., Lautenschlager, G., Hedden, T., Davidson, N. S., Smith, A. D., & Smith, P. K. (2002). Models of visuospatial and verbal memory across the adult life span. Psychology and Aging, 17, 299–320.CrossRefPubMed

Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999). Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology, 56, 303–308.CrossRefPubMed

Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., et al. (2007). Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease. Brain, 130, 2837–2844.CrossRefPubMed

Raz, N., & Rodrigue, K. M. (2006). Differential aging of the brain: patterns, cognitive correlates and modifiers. Neuroscience & Biobehavioral Reviews, 30, 730–748.CrossRef

Raz, N., & Kennedy, K. M. (2009). A systems approach to age-related change: Neuroanatomical changes, their modifiers, and cognitive correlates. In W. Jagust & M. D’Esposito (Eds.), Imaging the aging brain, Ch 4 (pp. 43–70). Oxford UP: NYC.

Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., et al. (2009). Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proceedings of the National Academy of Sciences, 106, 6820–6825.CrossRef

Rodrigue, K. M., & Raz, N. (2004). Shrinkage of the entorhinal cortex over five years predicts memory performance in healthy adults. Journal of Neuroscience, 24, 956–963.CrossRefPubMed

Rolstad, S., Nordlund, A., Eckerström, C., Gustavsson, M. H., Zetterberg, H., & Wallin, A. (2009). Biomarkers in relation to cognitive reserve in patients with mild cognitive impairment—proof of concept. Dementia and Geriatric Cognitive Disorders, 27, 194–200.CrossRefPubMed

Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., et al. (2007). Imaging beta-amyloid burden in aging and dementia. Neurology, 68, 1718–1725.CrossRefPubMed

Rowe, C. C., Ackerman, U., Browne, W., Mulligan, R., Pike, K. L., O’Keefe, G., et al. (2008). Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurology, 7, 129–135.CrossRefPubMed

Samuels, S. C., Silverman, J. M., Marin, D. B., Peskind, E. R., Younki, S. G., Greenberg, D. A., et al. (1999). CSF beta-amyloid, cognition, and APOE genotype in Alzheimer’s disease. Neurology, 52, 547–551.PubMed

Scheinin, N.M., Aalto, S., Koikkalainen, J., Lötjönen, J., Karrasch, M., Kemppainen, N., et al. (2009). Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology, 73, 1186–1192.

Schmidt, M. L., Lee, V. M., & Trojanowski, J. Q. (1990). Relative abundance of tau and neurofilament epitopes in hippocampal neurofibrillary tangles. American Journal of Pathology, 136, 1069–1075.

Selkoe, D. J. (2002). Alzheimer’s disease is a synaptic failure. Science, 298, 789–791.CrossRefPubMed

Shoghi-Jadid, K., Small, G. W., Agdeppa, E. D., Kepe, V., Ercoli, L. M., Siddarth, P., et al. (2002). Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. American Journal of Geriatric Psychiatry, 10, 24–35.PubMed

Skovronsky, D. (2008). Use of eINDs for evaluation of multiple related PET amyloid plaque imaging agents. Journal of Nuclear Medicine, 49, 47N–48N.PubMed

Skovronsky, D., Coleman, R. E., Frey, K., Garg, P., Ichise, M., Lowe, V., et al. (2008). Results of multi-center clinical trials comparing four 18F PET amyloid-imaging agents: preclinical to clinical correlations. Journal of Nuclear Medicine Meeting Abstracts, 49(1), 34P.

Small, G. W., Kepe, V., Ercoli, L. M., Siddarth, P., Bookheimer, S. Y., Miller, K. J., et al. (2006). PET of brain amyloid and tau in mild cognitive impairment. New England Journal of Medicine, 355, 2652–2663.CrossRefPubMed

Small, G. W., Bookheimer, S. Y., Thompson, P. M., Cole, G. M., Huang, S., Kepe, V., et al. (2008). Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurology, 7, 161–172.CrossRefPubMed

Small, G. W., Siddarth, P., Burggren, A. C., Kepe, V., Ercoli, L. M., Miller, K. J., et al. (2009). Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. Archives of General Psychiatry, 66, 81–87.CrossRefPubMed

Sperling, R. A., Laviolette, P. S., O’Keefe, K., O’Brien, J., Rentz, D. M., Pihlajamaki, M., et al. (2009). Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron, 63, 178–188.CrossRefPubMed

Stern, Y. (2002). What is cognitive reserve? Theory and research application of the reserve concept. Journal of the International Neuropsychological Society, 8, 448–460.CrossRefPubMed

Stern, Y. (2009). Cognitive reserve. Neuropsychologia, 47, 2015–2028.CrossRefPubMed

Strozyk, D., Blennow, K., White, L. R., & Launer, L. J. (2003). CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology, 60, 652–656.PubMed

Tapiola, T., Pirttilä, T., Mikkonen, M., Mehta, P. D., Alafuzoff, I., Koivisto, K., et al. (2000). Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer’s disease. Neuroscience Letters, 280, 119–122.CrossRefPubMed

Thal, D.R., Capetillo-Zarate, E., Del Tredici, K., & Braak, H. (2006). The development of amyloid beta protein deposits in the aged brain. Science of Aging Knowledge Environment: SAGE KE, 2006(6), re1.

Tolboom, N., Yaqub, M., van der Flier, W. M., Boellaard, R., Luurtsema, G., Windhorst, A. D., et al. (2009a). Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. Journal of Nuclear Medicine, 50, 191–197.CrossRefPubMed

Tolboom, N., Yaqub, M., Boellaard, R., Luurtsema, G., Windhorst, A.D., Scheltens, P., et al. (2009b). Test-retest variability of quantitative [(11)C]PIB studies in Alzheimer’s disease. European Journal of Nuclear Medicine and Molecular Imaging, 36, 1629–1638.

Villemagne, V. L., Pike, K. E., Darby, D., Maruff, P., Savage, G., Ng, S., et al. (2008). Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer’s disease. Neuropsychologia, 46, 1688–1697.CrossRefPubMed

Wahlund, L. O., & Blennow, K. (2003). Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neuroscience Letters, 339, 99–102.CrossRefPubMed

Wishart, H. A., Saykin, A. J., McAllister, T. W., Rabin, L. A., McDonald, B. C., Flashman, L. A., et al. (2006). Regional brain atrophy in cognitively intact adults with a single APOE epsilon4 allele. Neurology, 67, 1221–1224.CrossRefPubMed

Wong, D., Rosenberg, P., Zhou, Y., Kumar, A., Ravert, H., Brasic, J., et al. (2008). In vivo imaging of amyloid deposition in Alzheimer’s disease using the novel radioligand [18F] AV-45. Journal of Nuclear Medicine Meeting Abstracts, 49(1), 214P.

Zhang, W., Kung, M., Oya, S., Hou, C., & Kung, H. F. (2007). 18F-labeled styrylpyridines as PET agents for amyloid plaque imaging. Nuclear Medicine and Biology, 34, 89–97.CrossRefPubMed

Titel: Beta-Amyloid Deposition and the Aging Brain
verfasst von: Karen M. Rodrigue
Kristen M. Kennedy
Denise C. Park
Publikationsdatum: 01.12.2009
Verlag: Springer US
Erschienen in: Neuropsychology Review / Ausgabe 4/2009
Print ISSN: 1040-7308
Elektronische ISSN: 1573-6660
DOI: https://doi.org/10.1007/s11065-009-9118-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2009

Aging and Spatial Navigation: What Do We Know and Where Do We Go?

Decline and Compensation in Aging Brain and Cognition: Promises and Constraints

Aging, Training, and the Brain: A Review and Future Directions

Cognitive Aging Research: An Exciting Time for a Maturing Field

The Impact of Genetic Research on our Understanding of Normal Cognitive Ageing: 1995 to 2009